PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

GSK links with Medicago to develop novel COVID-19 vaccine

GSK and Canadian biopharma Medicago are joining forces on the development and evaluation of a COVID-19 candidate vaccine combining the former’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system.

CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system.

As adjuvants can boost the immune response and lessen the dose required they can be of particular importance in a pandemic situation, as they enable more vaccine doses to be produced.

Based on promising preclinical results of the vaccine, which demonstrated a high level of neutralising antibodies following a single dose when administered with adjuvant, Phase I clinical testing is scheduled to begin mid-July to assess the safety and immunogenicity of three different dose levels of antigen combined with GSKs pandemic adjuvant and in parallel with an adjuvant from another company.

The companies are hoping to complete development and make the vaccine available in the first half of 2021, using Medicago’s highly-scalable, plant-based production platform to manufacture the COVID-19 vaccine antigen, combined with GSKs proprietary adjuvant system.

The companies expect to be able to manufacture approximately 100 million doses by the end of 2021 and, by the end of 2023, a large-scale facility under construction in Quebec City, Canada, is expected to deliver up to 1 billion doses a year.

“This agreement paves the way for an innovative vaccine option combining a scalable plant-based antigen technology with an adjuvant which has pandemic dose sparing capability. If successful, it will be a meaningful contributor in the fight against COVID-19,” said Dr Thomas Breuer, chief medical officer, GSK Vaccines.

“We strongly believe that multiple vaccines are needed, including post-pandemic vaccines. This plant-based technology also shows promise beyond COVID-19 and has the potential to help prevent other infectious diseases.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026